19 May 2020ZEISS Group, Half-Year Press Conference 2019/20
Carl Zeiss AGHalf-Year Press ConferenceWeb Call19 May 2020 | 10 a.m.
Dr. Karl LamprechtPresident & CEO
Dr. Christian MüllerChief Financial Officer
All documents available for download:www.zeiss.com/pressconference
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 2
As of 31 March 2020All figures in euros.*Like-for-like
Revenue
3,213M+6% (+3%*)
Incoming orders
3,601M+14% (+10%*)
Consolidated profit
297M+16M
EVA
222M-32M
EBIT
455M+12M
Employees
31,906+5%
ZEISS Group First half of the fiscal year at a glance
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 3
EMEA
938M-3%*
Americas
652M+1%*
APAC
801M-4%*
Collaborations
822M+16%*
of which Germany
321M-8%*
ZEISS Group Global revenue distribution
Revenue trendDirect business in RDEs
682
1st six monthsof 2019/20
1st six monthsof 2018/19
673M-4%*
1st six months of 2019/20
Around 90 percent of revenue generated outside Germany
*Like-for-like compared to prior yearDirect-to-market business without collaborations (except for collaborations)
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 4
Sustained high demand in EUV and in DUV lithography systems
No significant impact due to the COVID-19 pandemic
1,634
2nd HY
1st HY
904M+18% (+17%*)
Revenue
Semiconductor Manufacturing Technology
1st six months of 2019/20
865
769
2019/202018/19
*Like-for-like
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 5
Metrology is experiencing a considerable impact due to the COVID-19 pandemic resulting from weak developments in the automobile industry
GOM leads to growth inoptical metrology
Microscopy business is stable
1,742
2nd HY
1st HY
922
820
865M+5% (-7%*)
Revenue
Industrial Quality & Research
1st six months of 2019/20
2019/202018/19
*Like-for-like
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 6
Ophthalmology and neurosurgery contribute to growth
Impact of the COVID-19 pandemic lead to a distinct weakening in Q2
1,760
2nd HY
1st HY
959
801
2019/20
834M+4% (+3%*)
Revenue
Medical Technology
1st six months of 2019/20
2018/19Not identical to Carl Zeiss Meditec AG.*Like-for-like
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 7
In the Consumer Markets segment, the Vision Care saw stable development in the first six months
Impact of the COVID-19 pandemic can already be felt strongly
1,211
2nd HY
1st HY
576M-3% (-3%*)
Revenue
Consumer Markets
1st six months of 2019/20
618
593
2019/202018/19
*Like-for-like
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 8
R&D expenditure totaled 12 percent of revenue to strengthen innovation power
705
2nd HY
1st HY
398M+76M
R&D expenditure
ZEISS Group
1st six months of 2019/20
383
322
2019/202018/19
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 9
Investments increased – sustainability becoming even more important437
2nd HY
1st HY
2018/19 2019/20
215M+82M
Investments in property, plant and equipment
ZEISS Group
1st six months of 2019/20
304
133
234
129
105
215
123
Investmentsin property, plant and equipment
Depreciationson property, plant and equipment
ZEISS Innovation Hub @ KIT
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 10
1,063
2nd HY
1st HY
2018/19 2019/20
455M+12M
Free cash flow
ZEISS Group
620
443
1,382
2nd HY
1st HY
2018/19
619M+33M
EBIT
796
586
2019/20
EBITDA
2018/19
180M-161M
2019/20
8062nd HY
1st HY
465
341
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20
1st six months of 2019/20
Consistent cost management as part of the resilience measures
Outlook
11
Liquidity situation remains stable1,740
30 September 2019
31 March2020
1,362M-186M
Gross and net liquidity
ZEISS Group
Gross liquidity
Net liquidity
1,548
1,3621,489
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 12
Equity ratio at 47 percent3,990
30 September 2019
31 March 2020
4,179M+5%
Equity
ZEISS Group
1st six months of 2019/20
4,179
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 13
Good development overall in first six months
Semiconductor Manufacturing Technology and Medical Technology segments in particular contribute to growth
Positive key performance indicators
Increased investment in R&D and digitalization
ZEISS Group Summary of first half of fiscal year
ImpactCOVID-19 pandemic
Drop in business across almost all areas
Semiconductor Manufacturing Technology segment still on track for growth
Resilience program launched early on proves effective
Safety, Continuity, Stability, Recovery
Portfolio servesmegatrends
Future-proof portfolio makes ZEISS strong and resilient
Acquisition of highly innovative units that can unlock their potential in the ZEISS portfolio
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20
Opportunities
Strong market position
Balanced portfolio driven by megatrends
Further opportunities through digital solutions and remote services
Increasing research expenditure globally in life sciences
Forecast
Difficult to form outlook
Impact of the COVID-19 pandemic leads to expectation for drop in revenue and EBIT
Economy
Global economy expected to face considerable challenges due to the COVID-19 pandemic
Economic uncertainty due to possible recession, changes to value chain, etc.
Measures
Focus on stability
Continuation of resilience measures
Safety, Continuity, Stability, Recovery
Maintaining innovative power
ZEISS Group Outlook for second half of fiscal year
14
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20 15
If you have any questions, please do not hesitate to contact us.
Jörg NitschkeZEISS GroupHead of Corporate Brand and CommunicationsPhone: +49 (0)7364 20-3242Email: [email protected]
All documents available for download:www.zeiss.com/pressconference
19 May 2020ZEISS Group, Half-Year Press Conference 2019/20